Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CLEVELAND, Aug. 6, 2013 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today that it has received a SBIR Fast Track grant from the National Heart, Lung, and Blood Institute, which will support a Phase 2 clinical study evaluating the administration of MultiStem® therapy to patients who have suffered a heart attack, or acute myocardial infarction (AMI). The grant is expected to provide up to $2.8 million in support over the course of the study in connection with study progress and milestone achievement.
Help employers find you! Check out all the jobs and post your resume.
